Uveal Melanoma Clinical Trial
Official title:
Assessing the Clinical Effectiveness of Serum Biomarkers in the Diagnosis of Metastatic Uveal Melanoma
Uveal melanoma is the most common primary intraocular tumor in adults. The local treatment
is effective, but patients still die of metastatic disease. It has been shown that early
diagnosis of a few isolated metastases can result in a clean surgical excision of the
metastases and an extension of the expected survival from 7-12 months to over 10 years on
some patients.
Many serum biomarkers are employed in Oncology. It makes sense to try the relevant ones in
the diagnosis of metastatic uveal melanoma.
The investigators hypothesis is that a soluble serum biomarker level changes upon
development of metastatic disease either by secretion by the tumor cells themselves or by
their environment. Detection of changes in biomarker level may lead to the diagnosis of
metastases before they can be detected by imaging modalities, thus allowing for early
treatment of the metastases and a better chance of success.
n/a
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04364230 -
Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)
|
Phase 1/Phase 2 | |
| Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
| Active, not recruiting |
NCT05542342 -
Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases.
|
Phase 2 | |
| Completed |
NCT02849145 -
Evaluation Interest of the Circulating Tumor DNA Dosage in Patient With Hepatic Metastatic Uveal Melanoma Candidate to Complete Resection (ct DNA R0)
|
N/A | |
| Not yet recruiting |
NCT00811200 -
Treatment Of Radiation Retinopathy Trial
|
Phase 2/Phase 3 | |
| Completed |
NCT00121225 -
Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma
|
Phase 2 | |
| Recruiting |
NCT05077280 -
A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma
|
Phase 2 | |
| Completed |
NCT03297424 -
A Study of PLX2853 in Advanced Malignancies.
|
Phase 1 | |
| Withdrawn |
NCT05482074 -
Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2
|
Phase 2 | |
| Completed |
NCT04551352 -
A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas
|
Phase 1 | |
| Not yet recruiting |
NCT06246149 -
Adjuvant Tebentafusp in High Risk Ocular Melanoma
|
Phase 3 | |
| Completed |
NCT01955941 -
Vascular Response to Brachytherapy Using Functional OCT
|
||
| Completed |
NCT00661622 -
Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF
|
Phase 2 | |
| Recruiting |
NCT05502900 -
Adjuvant Melatonin for Uveal Melanoma
|
Phase 3 | |
| Active, not recruiting |
NCT03070392 -
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
|
Phase 2 | |
| Recruiting |
NCT06284512 -
Uveal Melanoma - Comparative Study
|
||
| Recruiting |
NCT05524935 -
Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
|
Phase 2 | |
| Active, not recruiting |
NCT02913417 -
Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06073548 -
Patient Experience and Quality of Life During the Surveillance Phase of Uveal Melanoma: A Prospective Multi-method Study
|
||
| Recruiting |
NCT06075589 -
Psychoeducation for Uveal Melanoma
|